Study on BMS986365 and Degarelix for Prostate Cancer Treatment

Inclusion Criteria

• Must be willing to provide written consent and allow access to personal health information.
• Men aged 18 and older with prostate cancer.
• Must have confirmed prostate cancer through lab tests.
• Must have high-risk localized prostate cancer, defined by:
  • PSA level of 20 ng/ml or higher
  • Gleason score of 8 or higher
  • Clinical stage of cT3a or higher
• Must be a candidate for surgery as determined by a doctor.
• Must have a performance status score of 2 or lower, indicating good overall health.
• Must have normal organ function and acceptable lab test results within 28 days before starting the study.
• Must agree to use effective contraception during the study and for a specified period after the last dose.
• Must not donate sperm during the study and for a specified period after the last dose.

Exclusion Criteria

• Evidence of prostate cancer spread beyond the pelvis.
• On hormone therapy for more than 4 weeks at the time of consent.
• Previous systemic therapy for prostate cancer, such as chemotherapy or immunotherapy.
• Previous local treatments to the prostate, like radiation or phototherapy.
• Considered a poor medical risk due to serious health issues or recent surgery.
• Unable to swallow pills or have digestive issues affecting absorption.
• Heart problems or significant heart disease, including:
  • Low heart function or abnormal heart rhythms
  • History of serious heart conditions
  • Taking medications that affect heart rhythms
• Recent heart failure or heart attack.
• Poorly controlled high blood pressure.
• Recent significant blood clots.
• Active viral hepatitis or HIV with certain conditions.
• Other active cancers requiring treatment, except for certain skin or bladder cancers.
• Use of certain medications or supplements that are not allowed during the study.
• Participation in another clinical trial or use of investigational drugs recently.
• Known allergy to study drugs.
• Any other condition that would prevent participation in the study.